193 related articles for article (PubMed ID: 24155778)
1. UCHL1 Is a Putative Tumor Suppressor in Ovarian Cancer Cells and Contributes to Cisplatin Resistance.
Jin C; Yu W; Lou X; Zhou F; Han X; Zhao N; Lin B
J Cancer; 2013; 4(8):662-70. PubMed ID: 24155778
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.
Yu J; Tao Q; Cheung KF; Jin H; Poon FF; Wang X; Li H; Cheng YY; Röcken C; Ebert MP; Chan AT; Sung JJ
Hepatology; 2008 Aug; 48(2):508-18. PubMed ID: 18666234
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.
Ummanni R; Jost E; Braig M; Lohmann F; Mundt F; Barett C; Schlomm T; Sauter G; Senff T; Bokemeyer C; Sültmann H; Meyer-Schwesinger C; Brümmendorf TH; Balabanov S
Mol Cancer; 2011 Oct; 10():129. PubMed ID: 21999842
[TBL] [Abstract][Full Text] [Related]
4. The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer.
Xiang T; Li L; Yin X; Yuan C; Tan C; Su X; Xiong L; Putti TC; Oberst M; Kelly K; Ren G; Tao Q
PLoS One; 2012; 7(1):e29783. PubMed ID: 22279545
[TBL] [Abstract][Full Text] [Related]
5. The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma.
Li L; Tao Q; Jin H; van Hasselt A; Poon FF; Wang X; Zeng MS; Jia WH; Zeng YX; Chan AT; Cao Y
Clin Cancer Res; 2010 Jun; 16(11):2949-58. PubMed ID: 20395212
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous expression and biological function of ubiquitin carboxy-terminal hydrolase-L1 in osteosarcoma.
Zheng S; Qiao G; Min D; Zhang Z; Lin F; Yang Q; Feng T; Tang L; Sun Y; Zhao H; Li H; Yu W; Yang Y; Shen Z; Yao Y
Cancer Lett; 2015 Apr; 359(1):36-46. PubMed ID: 25578779
[TBL] [Abstract][Full Text] [Related]
7. [The role of hypermethylation in promoter region of ubiquitin carboxyl-terminal hydrolase L1 in human esophageal cancer].
Yan WJ; Guo MZ; Yang YS
Zhonghua Nei Ke Za Zhi; 2012 May; 51(5):390-3. PubMed ID: 22883340
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Mediates the Reversal Effect of Verapamil on Chemo-Resistance to Adriamycin of Hepatocellular Carcinoma.
Yang G; Fan G; Zhang T; Ma K; Huang J; Liu M; Teng X; Xu K; Fan P; Cheng D
Med Sci Monit; 2018 Apr; 24():2072-2082. PubMed ID: 29627846
[TBL] [Abstract][Full Text] [Related]
9. Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance.
Trifa F; Karray-Chouayekh S; Jmaa ZB; Jmal E; Khabir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
Med Oncol; 2013 Mar; 30(1):418. PubMed ID: 23315218
[TBL] [Abstract][Full Text] [Related]
10. CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) and P53 mutation pattern in sporadic colorectal cancer.
Abdelmaksoud-Dammak R; Saadallah-Kallel A; Miladi-Abdennadher I; Ayedi L; Khabir A; Sallemi-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
Tumour Biol; 2016 Feb; 37(2):1707-14. PubMed ID: 26314856
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma.
Seliger B; Handke D; Schabel E; Bukur J; Lichtenfels R; Dammann R
J Transl Med; 2009 Oct; 7():90. PubMed ID: 19857250
[TBL] [Abstract][Full Text] [Related]
12. Silencing of the UCHL1 gene in human colorectal and ovarian cancers.
Okochi-Takada E; Nakazawa K; Wakabayashi M; Mori A; Ichimura S; Yasugi T; Ushijima T
Int J Cancer; 2006 Sep; 119(6):1338-44. PubMed ID: 16642472
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma.
Wulfänger J; Biehl K; Tetzner A; Wild P; Ikenberg K; Meyer S; Seliger B
Int J Cancer; 2013 Dec; 133(11):2522-32. PubMed ID: 23686552
[TBL] [Abstract][Full Text] [Related]
14. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
[TBL] [Abstract][Full Text] [Related]
15. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin carboxyl-terminal hydrolase L1 promotes hypoxia-inducible factor 1-dependent tumor cell malignancy in spheroid models.
Li X; Hattori A; Takahashi S; Goto Y; Harada H; Kakeya H
Cancer Sci; 2020 Jan; 111(1):239-252. PubMed ID: 31729096
[TBL] [Abstract][Full Text] [Related]
17. Cancer detection by ubiquitin carboxyl-terminal esterase L1 methylation in pancreatobiliary fluids.
Kato N; Yamamoto H; Adachi Y; Ohashi H; Taniguchi H; Suzuki H; Nakazawa M; Kaneto H; Sasaki S; Imai K; Shinomura Y
World J Gastroenterol; 2013 Mar; 19(11):1718-27. PubMed ID: 23555160
[TBL] [Abstract][Full Text] [Related]
18. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin carboxyl-terminal esterase L1 (UCHL1) is associated with stem-like cancer cell functions in pediatric high-grade glioma.
Sanchez-Diaz PC; Chang JC; Moses ES; Dao T; Chen Y; Hung JY
PLoS One; 2017; 12(5):e0176879. PubMed ID: 28472177
[TBL] [Abstract][Full Text] [Related]
20. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
